David Resnick
Allergy · West Nyack, NYNPI 1922064435
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $555 of the $694 with a category attached, or 80.1%. 11 manufacturers reported payments, led by GSK at 25.9% of the total. 2025 is the largest year on record at $572, more than ten times the $39 reported in 2019. That places this record below the midpoint for allergy clinicians in NY, where the typical reported total is $1,727.
Across 34 payments — averaging $20.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$180
- Novartis$120
- AstraZeneca$104
- Galderma Laboratories, L.p.$95
- CSL Behring$41
- ADMA Biomanufacturing LLC$38
- plus $116 from 5 others
What the payments were for
- Consulting fees$385%
- Speaking & faculty fees$254%
- Food & beverage$55580%
- Education$7511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $180 |
| Novartis | 5 | $120 |
| AstraZeneca | 1 | $104 |
| Galderma Laboratories, L.p. | 1 | $95 |
| CSL Behring | 2 | $41 |
| ADMA Biomanufacturing LLC | 4 | $38 |
| Amgen | 1 | $34 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Biocryst US Sales Co., LLC | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$104
How this compares
$694 in reported general payments places this provider in the 40th percentile of 92 allergy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CinryzeC1 Esterase Inhibitor | 14 | $709,436 |
| HaegardaC1 Esterase Inhibitor | 13 | $639,216 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $120,920 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 110 | $91,702 |
| Dupixent SyringeDupilumab | 22 | $89,457 |
| XolairOmalizumab | 26 | $71,674 |
| Breo ElliptaFluticasone/Vilanterol | 81 | $40,431 |
| Advair HfaFluticasone Propion/Salmeterol | 61 | $25,366 |
| Arnuity ElliptaFluticasone Furoate | 44 | $15,736 |
| Epinephrine | 37 | $7,967 |
| Ipratropium Bromide | 152 | $5,713 |
| DuleraMometasone/Formoterol | 13 | $5,182 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 47 | $5,045 |
| Levocetirizine Dihydrochloride | 176 | $4,867 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 105 | $3,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHaegarda, Hizentra | $41 | $760,13627 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cinryze | $23 | $709,43614 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $180 | $147,870235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 allergy providers in New York.
Other allergy in West Nyack
- Peter LogalboWest Nyack$4K
- Marc BraunsteinHewlett$884K
- Allison RamseyRochester$643K
- Christopher SmithHorseheads$622K
- Anne MaitlandTarrytown$292K
- Yudhistira PersaudBronx$127K
- Michael KatlanAlbany$91K
- Michel AklJamestown$90K
- Juan SotomayorNorth Syracuse$64K
- Alan KaufmanMount Vernon$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.